A method of reducing the opioid withdrawal intensity using progressively increasing doses of naloxone

Journal of Pharmacological and Toxicological Methods

Volumn 42, Issue 3, 1999, Pages 115-119

  Langerman, Lev ^a   Steingart, Ruth A ^a   Margolis, Anatoly ^a   Yanai, Joseph ^a  

^a H   (Israel)

Author keywords

Addiction; Mice; Morphine; Opioids; Withdrawal

Indexed keywords

MORPHINE DERIVATIVE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG WITHDRAWAL; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; MOVEMENT DISORDERS; NALOXONE; NARCOTIC ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0033304770     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(00)00039-3     Document Type: Article

References (30)

1. Altman J.L., Meyer R.E., Mirin S.M., McNamee H.B., McDougle M. Opiates antagonists and the modification of heroin self-administration behavior in man. an experimental study Int J Addict. 11:1976;485-499.
2. Brewer C. Naltrexone. helping the heroin user to get clean and stay clean (editorial) Br J Hosp Med. 36:1986;6.
3. Brewer C. Combining pharmacological antagonists and behavioral psychotherapy in treating addictions. Why it is effective but unpopular. Br J Psychiatry. 157:1990;34-40.
4. Dai S., Corrigall W.A., Coen K.M., Kalant H. Heroin self-administration by rats. influence of dose and physical dependence Pharmacol Biochem Behav. 32:1989;1009-1015.
5. Frances B., Gout R., Cross J., Zajac J.M. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundamental Clin Pharmaco. 6:1992;327-332.
6. Gold M.S., Rea W.S. The role of endorphins in opiate addiction, opiate withdrawal, and recovery. Psychiatr Clin North Am. 6:1983;489-520.
7. Gonzalez J.P., Brogden R.N. Naltrexone. a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence Drugs. 35:1988;192-213.
8. Greenstein R.A., Arndt I.C., McLellan A.T., O'Brien C.P., Evans B. Naltrexone. a clinical perspective J Clin Psychiatr. 45:1984;25-28.
9. Heishman S.J., Stitzer M.L., Bigelow G.E., Liebson I.A. Acute opioid physical dependence in humans. effect of naloxone at 6 and 24 hours postmorphine Pharmacol Biochem Behav. 36:1990;393-399.
10. Johnson S.M., Fleming W.W. Mechanisms of cellular adaptive sensitivity changes. applications to opioid tolerance and dependence Pharmacol Rev. 41:1989;435-488.
11. Kimes A.S., Vaupel D.B., London E.D. Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. Psychopharmacology. 112:1993;521-524.
12. Legarda J.J., Gossop M. A 24-h inpatient detoxification treatment for heroin addicts. a preliminary investigation Drug Alcohol Depend. 35:1994;91-93.
13. Lerner A.G., Sigal M., Gelkopf M. Naltrexone abuse and risk of suicide. J Nerv Ment Dis. 181:1993;706-707.
14. Loimer N., Lenz K., Schmid R., Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry. 148:1991;933-935.
15. Loimer N., Schmid R.W., Presslich O., Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res. 23:1989;81-86.
16. Marshall I., Weinstock M. Quantitative method for assessing one symptom of the withdrawal syndrome in mice after chronic morphine administration. Nature. 234:1971;223-224.
17. Miyamoto Y., Takemori A.E. Inhibition of naloxone-precipitated withdrawal jumping by ICV and IT administration of saline in morphine-dependent mice. Life Sci. 52:1993;1129-1134.
18. Nestler E.J. Feature article - molecular mechanisms of drug addiction. J Neurosci. 12:1992;2439-2450.
19. O'Connor P.G., Kosten T.R. Rapid and ultrarapid opioid detoxification techniques. JAMA. 279:1998;229-234.
20. Presslich O., Loimer N., Lenz K., Schmid R. Opiate detoxification under general anesthesia by large doses of naloxone. Clin Toxicol. 27:1989;263-270.
21. Rabinowitz J., Cohen H., Tarrasch R., Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxification. an open label naturalistic study Drug Alcohol Depend. 47:1997;77-86.
22. Rafieian-Kopaei M., Gray A.M., Spencer P.S., Sewell R.D. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning. Eur J Pharmacol. 275:1995;185-189.
23. Rasmussen K., Beitner-Johnson D., Krystall J.H., Aghajanian G.K., Nestler E.G. Opiate withdrawal and the rat locus coeruleus. behavioral, electrophysiological, and biochemical correlates J Neurosci. 10:1990;2308-2317.
24. Ronnback L., Eriksson P.S., Zeuchner J., Rosengren L., Wronski A. Aspects of abstinence after morphine ingestion. Pharmacol Biochem Behav. 28:1987;87-93.
25. Shufman E.N., Porat S., Witztum E., Gandacu D., Bar-Hamburger R., Ginath Y. The efficacy or naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 35:1994;935-945.
26. Sideroff S.I., Charuvastra J.C., Jarvik M.E., Ouren J. Craving in heroin addicts maintained on opiate antagonist naltrexone. Am J Drug Alcohol Abuse. 5:1978;415-423.
27. Simon M.I., Strathmann M.P., Gautam N. Diversity of Gproteins in signal transduction. Science. 252:1991;802-808.
28. Tanganelli S., Antonelli T., Morari M., Bianchi C., Beani L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neuroscience Letters. 122:1991;270-272.
29. Tierney C., Naduad D., Koenig-Berard E., Stinus L. Effects of two alpha2 agonists, rilmenidine and clonidine, on the morphine withdrawal syndrome and their potential addictive properties in rats. Am J Cardiol. 61:1988;35-38.
30. Trujillo K.A., Akil H. Opiate tolerance and dependence. recent findings and synthesis New Biol. 3:1991;915-923.